| 1 |
Dr. M. Gopichand |
A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy. |
“Phase 3/ Phase 4” |
0063-17 |
Metastatic Breast Cancer |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2018/06/014390 |
M V Subbarao,+91-9642611888 |
| 2 |
Dr. K. Lakshmi Priyadarshini |
A single arm, multicentric, open label, efficacy and safety study of Docetaxel Lipid Suspension for Injection of Intas Pharmaceuticals Limited, India in patients with Metastatic Castration Resistant prostate cancer |
Phase 4 |
0329-17 |
Metastatic Castration Resistant prostate Cancer |
Department of Medical Oncology |
Recruitment completed. |
CTRI/2018/02/012212 |
M V Subbarao,+91-9642611888 |
| 3 |
Dr. K. Lakshmi Priyadarshini |
“A Randomized, Multiple-dose, Multicenter, Comparative, Parallel Study to
Evaluate the Efficacy, Safety and Pharmacokinetic Characteristics of
Intravenous Infusion of Trastuzumab (Test, Hetero) and Reference Medicinal Product (Reference, Roche) in combination with standard chemotherapy in Patients of HER2-positive Metastatic breast cancer (TRUMAB Study)” |
Phase 3 |
HCR/III/TRUMAB/05/2016 |
Metastatic Breast Cancer |
Department of Medical Oncology |
Recruitment completed. |
CTRI/2019/03/018009 |
M V Subbarao,+91-9642611888 |
| 4 |
Dr. K. Pavan Raghavareddy |
A Multicenter, Double-Blind, Randomized, Parallel- Group, Active-Controlled, Two Part, Phase III, Global Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison with Herceptin®-EU in Patients with HER2-Positive Early Breast Cancer (EBC) and HER2-Positive Metastatic Breast Cancer (MBC). |
Phase 3 |
CR201-18 |
HER2-Positive Early Breast Cancer (EBC) and HER2-Positive Metastatic Breast Cancer (MBC) |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2020/04/024456 |
M V Subbarao,+91-9642611888 |
| 5 |
Dr.M.Gopichand |
A multicenter, open-label, randomized, study to evaluate the efficacy and safety of Paclitaxel Lipid Suspension for Injection in patients with recurrent metastatic ovarian carcinoma |
|
0351-20 |
Metastatic Ovarian Carcinoma |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2020/09/028042 |
M V Subbarao,+91-9642611888 |
| 6 |
Dr. K. Pavan Raghavareddy |
A Phase II Clinical Study to evaluate the efficacy and safety of NRC-2694-A in patients with recurrent Head and Neck Squamous Cell Carcinoma |
Phase 2 |
NAT2694P2 |
Head and Neck Squamous Cell Carcinoma |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2019/06/019649 |
M V Subbarao,+91-9642611888 |
| 7 |
Dr. K. Pavan Raghavareddy |
A Randomized, Open Label, Multi-Center, Two-Treatment, Two-Period, Two-Sequence, Two-Way Crossover, Multiple Dose, Steady-State Bioequivalence (BE) Study of Pazopanib HCl 200mg Tablets at a Dose of 800 mg (4 * 200 mg tablets) of Lotus Pharmaceutical CO., Ltd., Taiwan with VOTRIENT® (Pazopanib HCl 200mg) Tablets at a Dose of 800 mg (4 * 200 mg tablets) of Novartis Pharmaceuticals Corporation, USA in Subjects with Advanced Renal Cell Carcinoma Under Fasting Condition |
|
CBCC/2020/018 |
Advanced Renal Cell Carcinoma |
Department of Medical Oncology |
Recruitment completed. |
CTRI/2020/11/029079 |
M V Subbarao,+91-9642611888 |
| 8 |
Dr. K.L. Priyadarshini |
A multicenter, open label, randomized, balanced, two treatment, three periods, three sequence, reference replicate, crossover, single dose, bioequivalence study of Doxorubicin Hydrochloride Liposome Injection 2 mg/mL of ForDoz Pharma Corp., USA with Doxorubicin Hydrochloride Liposome Injection for intravenous infusion 2 mg/mL Manufactured By: Sun Pharmaceutical Industries Ltd., India, administered in female patients with ovarian cancer whose disease has progressed or recurred after platinum based chemotherapy and who are already receiving or scheduled to start therapy with doxorubicin hydrochloride liposome injection under fasting conditions. |
|
18-VIN-0553 |
Ovarian Cancer |
Department of Medical Oncology |
Recruitment completed. |
CTRI/2021/03/032185 |
M V Subbarao,+91-9642611888 |
| 9 |
Dr. M. Gopichand |
A Randomised, Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of DRL_RI with MabThera® in Subjects with Previously Untreated, Stage II-IV, CD20-Positive, Low Tumour Burden Follicular Lymphoma |
Phase 3 |
RI-01-006 |
Follicular Lymphoma |
Department of Medical Oncology |
Recruitment completed. |
CTRI/2019/05/019044 |
M V Subbarao,+91-9642611888 |
| 10 |
Dr. K. Pavan Raghavareddy |
Prospective, multicenter, randomized, double blind Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer |
Phase 3 |
ALKEM |
Metastatic Colorectal Cancer |
Department of Medical Oncology |
Recruitment completed. |
CTRI/2020/06/025851 |
M V Subbarao,+91-9642611888 |
| 11 |
Dr Gopichand |
A prospective Multicentre Phase IV study to evlauvate and efficay of Dr Reddy’s Bevacizumab in patients with solid tumors |
Phase 4 |
BZ-01-002 |
Solid Tumors |
Department of Medical Oncology |
Recruitment completed. |
CTRI/2020/08/027333 |
M V Subbarao,+91-9642611888 |
| 12 |
Dr. Priyadarshini |
A randomized, open label, multi-center, two-treatment, three-period, three-sequence,reference replicate, multiple dose, steady-state, bioequivalence (BE) study of Olaparib Tablets 150 mg (2*150 mg tablets) of Natco Pharma Limited with LYNPARZA®(Olaparib) tablets 150 mg (2*150 mg tablets) of AstraZeneca Pharmaceuticals LP,Wilmington, DE 19850, in male or female patients with ovarian cancer or breast cancer or prostate cancer. |
|
CBCC/2020/032 |
Ovarian Cancer or Breast Cancer or Prostate Cancer |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2021/08/035525 |
M V Subbarao,+91-9642611888 |
| 13 |
Dr Gopichand |
Standard Chemotherapy versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer |
|
Chemo ID |
Recurrent Platinum Resistant Ovarian Cancer |
Department of Medical Oncology |
Recruitment Ongoing |
|
M V Subbarao,+91-9642611888 |
| 14 |
Dr Gopichand |
Efficacy of GDC-9545 as adjuvant treatment in patients with ER-positive, HER2-negative early Breast Cancer (EBC). This Phase III, global, randomized, open-label, two-arm study will evaluate the efficacy, safety, and pharmacokinetics of GDC-9545 compared with physician’s choice of endocrine monotherapy in the adjuvant setting. |
Phase 3 |
GO42784 |
ER-positive, HER2-Negative Early Breast Cancer |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2022/01/039625 |
M V Subbarao,+91-9642611888 |
| 15 |
Dr M Gopichand |
A multicenter, open label, randomized, balanced, two,treatment, three period,three sequence, single dose, replicate cross over bioequivalence study of treatment, three period,three sequence, single dose, replicate cross over bioequivalence study of three sequence, single dose, replicate cross over bioequivalence study of Doxorubicin Hydrochloride Pegylated Liposome Injection 2mg/mL (50 mg/m2 |
|
CBCC/2020/004 |
Ovarian Cancer |
Department of Medical Oncology |
Recruitment completed. |
CTRI/2020/08/027025 |
M V Subbarao,+91-9642611888 |
| 16 |
Dr Priyadrshini |
A multicenter, open label, randomized, balanced, two-treatment, two-period, two-sequence, single dose, cross-over bioequivalence study of Doxorubicin hydrochloride liposome injection 2mg/mL (50 mg/m2 dose) of Sun Pharmaceutical Industries Ltd., India with that of DOXIL® (Doxorubicin hydrochloride liposome injection) 2mg/mL (50 mg/m2 dose) of Janssen Pharmaceutical, Tokyo, Japan in patients with platinum resistant recurrence or relapse mullerian carcinoma (epithelial ovarian cancer, primary fallopian tube cancer, peritoneal cancer) under fed (standardized light meal) condition |
|
CBCC/2020/034 |
mullerian carcinoma |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2022/01/039082 |
M V Subbarao,+91-9642611888 |
| 17 |
Dr. M. Gopichand |
“Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate for Injection 3.75mg (Depot) Administered in Subjects with Advanced Adenocarcinoma of Prostate: A Randomized, Active Controlled, Comparative, Open Label, Multi- Center, Phase 3 study BSV-LEUPR-18-05” |
Phase 3 |
BSV_LEUPR_18-05 |
Prostate Cancer |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2019/11/021843 |
M V Subbarao,+91-9642611888 |
| 18 |
Dr Priyadrshini |
A Phase IIb/III, Randomised, Double-blind, Placebo controlled, Multicentre, Study of CA-170 in Combination with Chemotherapy in Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer (ASIAD-3). |
Phase 2b/3 |
CA-170-302 (ASIAD-3) |
NSCLC |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2021/10/037699 |
M V Subbarao,+91-9642611888 |
| 19 |
Dr Priyadrshini |
A randomized, open label, multi-centre, two-treatment, two-period, two-sequence, two stage, multiple dose, steady-state, crossover, bioequivalence study of Olaparib tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (olaparib) tablets 150 mg (AstraZeneca Pharmaceuticals LP), in patients with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer under fasting condition |
|
21-VIN-0166 |
Recurrent Ovarian or Metastatic Breast Cancer |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2022/03/040741 |
M V Subbarao,+91-9642611888 |
| 20 |
Dr Priyadrshini |
A Phase II, Open-Label Trial, Evaluating the Efficacy and Safety of Once Daily Oral ODM-203 in Patients with Unresectable Transitional Cell Urothelial Carcinoma with FGFR3 Mutation (TEJAS-1). |
Phase 2 |
ODM-203-201 (TEJAS-1 Study) |
Unresectable Transitional Cell Urothelial Carcinoma with FGFR3 Mutation |
Department of Medical Oncology |
Recruitment Ongoing |
CTRI/2021/11/038092 |
M V Subbarao,+91-9642611888 |
| 21 |
Dr Gopichand |
Collection of blood samples from subjects diagnosed with Non-Small Cell Lung Carcinoma to evaluate biomarker expression profiles |
|
SLS-GNE-02 |
NSCLC |
Department of Medical Oncology |
Ongoing |
NA |
M V Subbarao,+91-9642611888 |
| 22 |
Dr Gopichand |
COllection of blood And Tissue Samples From Subjects diagnosed with Esophageal cancer to Evaluate Biomarker Expression profiles |
|
SLS-GNE-01 |
Esophagus Cancer |
Department of Medical Oncology |
Ongoing |
NA |
M V Subbarao,+91-9642611888 |
